158
G. Yang and Y. Huang
Table 6.3
(continued)
Targeting platform
Therapeutic agents
Target cell line
In vitro/In vivo Ref.
Porous silicon
Methotrexate/sorafenib
MDA-MB-231
Y/N
[215]
PEG magnetic MSN
Dox
MCF-7
Y/N
[216]
Graphene oxide- dextran
Curcumin
4T1, MCF-7
Y/N
[217]
Gold nanospheres
Gold nanospheres
MCF-7, MDA-MB-231
Y/Y
[218]
Gold nanostar
Gold nanostar
HT-1080, MDA-MB-231 Y/Y
[219]
Gold nanoparticles
NLS peptide/anti-miR 221
NB4, HL60
Y/Y
[220]
Gold nanoparticles
Gold nanoparticles
HeLa
Y/N
[221]
Silver and gold nanoparticle
Dox
HeLa
Y/N
[222]
Silver nanoclusters
Dox
MCF-7
Y/N
[223]
Liposome
Dox
MCF-7
Y/Y
[224]
PEG-liposome
anti-BRAF siRNA
A375
Y/Y
[225]
Liposome
Dox/ammonium bicarbonate
MCF-7/ADR
Y/Y
[226]
Liposome
PLK1 siRNA/Paclitaxel
MCF-7
Y/Y
[227]
Liposome
Dox
MCF-7/ADR
Y/N
[204]
Niosomes
Ru(III) complex HoThyRu
HeLa
Y/N
[228]
Albumin nanoparticles
Dox
MCF-7
Y/N
[229]
Albumin nanoparticles
5-FU, BpT
Bel-7402
Y/Y
[230]
Albumin nanoparticles loaded on gold and iron oxide nanoparticles Dox
MCF-7
Y/N
[231]